Current perspectives: obesity and neurodegenerationlinks and risks
Novo estimates 1.5 million US users of compounded GLP-1s
The most affected product categories include chips & savory snacks (-11%), sweet bakery items (-9%) and soft drinks (-7%), which translates into short-to-medium term losses of USD 7.5-8 bn within these segments in the US market
The 2.5 mg dose is better called the low-dose starter, because it is the labeled start and now has short direct non-diabetic data behind it. Microdosing has been used for tolerability testing, metabolic-marker support, step-down protocols, and maintenance, not for proven long-term obesity outcomes
But federally funded Medicare does not cover obesity medicines, and Medicaid covers one or more weight-loss drugs in only 16 states, according to KFF, a health policy research nonprofit
Ozempic is a medication that mimics the effects of GLP-1 to promote weight loss by decreasing hunger and improving satiety